Plazomicin is a next-generation aminoglycoside antibiotic developed to combat multidrug-resistant bacterial infections, including those caused by Enterobacteriaceae. It operates by binding to bacterial ribosomal RNA, thus inhibiting protein synthesis and leading to bacterial death. Plazomicin is specifically designed to evade the mechanisms that commonly confer resistance to older aminoglycosides, making it a valuable treatment option for serious infections such as complicated urinary tract infections and bloodstream infections, particularly in hospital settings where resistant pathogens are prevalent.
| Catalog Number | R057829 |
| CAS Number | 1154757-24-0 |
| Synonyms | O-2-Amino-2,3,4,6-tetradeoxy-6-[(2-hydroxyethyl)amino]-α-D-glycero-hex-4-enopyranosyl-(1→4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1→6)]-N1-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-D-streptamine; ACHN 490; |
| Molecular Formula | C25H48N6O10 |
| Purity | 95% |
| Storage | Store at -20°C |
| IUPAC Name | (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[[(2S,3R)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2H-pyran-2-yl]oxy]-2-[(2R,3R,4R,5R)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide |
| InChI | InChI=1S/C25H48N6O10/c1-25(37)11-38-24(18(35)21(25)29-2)41-20-15(31-22(36)16(33)5-6-26)9-14(28)19(17(20)34)40-23-13(27)4-3-12(39-23)10-30-7-8-32/h3,13-21,23-24,29-30,32-35,37H,4-11,26-28H2,1-2H3,(H,31,36)/t13-,14+,15-,16+,17+,18-,19-,20+,21-,23-,24-,25+ m1 s1 |
| InChIKey | IYDYFVUFSPQPPV-PEXOCOHZSA-N |
| SMILES | CC1(COC(C(C1NC)O)OC2C(CC(C(C2O)OC3C(CC=C(O3)CNCCO)N)N)NC(=O)C(CCN)O)O |
